Apolipoprotein C-III and E polymorphisms and cardiovascular syndrome, hyperlipidemia, and insulin resistance in renal transplantation.
Hyperlipidemia and insulin resistance frequently develop after renal transplantation, contributing to cardiovascular disease. Individual differences in response based upon genetic variations in proteins regulating lipidic and glucose tolerance metabolism could be expected. In the general population, the S2 allelic variant of the apoprotein (apo) C-III gene has been associated with hypertriglyceridemia and an insulin resistant state, whereas the E4 allele of the apo E has been associated with hypercholesterolemia and atherosclerosis. Its influence in renal transplant patients remains to be seen. In order to assess the impact of apo E and C-III major polymorphisms on atherosclerotic vascular disease, lipid profile and impaired glucose tolerance in renal transplant patients, we studied 110 consecutively examined patients undergoing kidney transplantation (age range 24-73 years). Atherosclerotic complications were detected in 25% of patients, with age, male sex and hypercholesterolemia being significant atherosclerotic risk factors. Among the male patients with E4 allele, the odds ratio for coronary disease and global atherosclerosis were 10.2 (95% CI) and 6.4 (95% CI), respectively. There were no significant differences in the frequency of any of the polymorphisms among patients with dyslipidemia and impaired glucose tolerance. As the number of patients in our sample was small, larger studies are needed to verify these issues. While in the studied population C-III polymorphism appears to have little association with the prevalence of atherosclerotic complications, E4 allele should be considered as a genetic marker of coronary artery disease and global atherosclerosis in renal transplant patients.
Department of Nephrology, Hospital Valdecilla University of Cantabria, Santander, Spain. nefrce@humv.es
Emilio
E
Rodrigo
Domingo
D
González-Lamuño
Juan Carlos
JC
Ruiz
Gema
G
Fernández-Fresnedo
Débora
D
Isla
Julio
J
González-Cotorruelo
José Antonio
JA
Zubimendi
Angel Luis Martín
AL
De Francisco
Miguel
M
García-Fuentes
Manuel
M
Arias
D000328:Adult; D000368:Aged; D053305:Apolipoprotein C-III; D001056:Apolipoproteins C / Q000235:genetics*; D001057:Apolipoproteins E / Q000235:genetics*; D001161:Arteriosclerosis / Q000097:blood / Q000150:complications / Q000235:genetics; D002784:Cholesterol / Q000097:blood; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood / Q000235:genetics; D005260:Female; D005787:Gene Frequency; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000235:genetics*; D007333:Insulin Resistance / Q000235:genetics*; D016030:Kidney Transplantation; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications / Q000235:genetics*; D008875:Middle Aged; D011110:Polymorphism, Genetic / Q000235:genetics*; D014280:Triglycerides / Q000097:blood
D053305:Apolipoprotein C-III; D001056:Apolipoproteins C; D001057:Apolipoproteins E; D014280:Triglycerides; D002784:Cholesterol